Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 6/2000

01-06-2000 | Review Article

Role of Newer Atypical Antipsychotics in the Management of Treatment-Resistant Schizophrenia

Author: Prof. Robin A. Emsley

Published in: CNS Drugs | Issue 6/2000

Login to get access

Abstract

This article reviews the evidence of the effects of atypical antipsychotics other than clozapine in patients with schizophrenia that is resistant to treatment with conventional agents. Clozapine remains the one drug with proven efficacy in patients with severely refractory symptoms. However, while the drug is modestly effective in 30 to 70% of these patients, there are many who are either intolerant of, or unresponsive to, it.
The initial hope that the new atypical antipsychotics would play a major role in treatment-resistant schizophrenia has not really materialised. Nevertheless, it is increasingly recognised that perhaps the majority of patients with schizophrenia have milder degrees of refractoriness — so-called ‘partial responders’ — and considerable evidence is emerging for an important role for risperidone, olanzapine and quetiapine in these patients. These drugs appear to have advantages over the conventional antipsychotics in terms of both efficacy and tolerability in these patients.
More studies are required to establish optimal dosages of the atypical antipsychotics in patients with refractory symptoms, as well as whether some individuals respond differentially to a particular drug.
Literature
1.
2.
Carman J, Peuskens J, Vangeneugden A. Risperidone in thetreatment of negative symptoms of schizophrenia: a meta-analysis.Int J Psychopharmacol 1995; 10: 207–13CrossRef
3.
Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55(3): 250–8PubMedCrossRef
4.
Meltzer H, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact onrisk-benefit assessment. Am J Psychiatry 1995; 152: 183–90PubMed
5.
Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptomsand cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997; 95: 40–3PubMedCrossRef
6.
Franz M, Lis S, Pluddemann K, et al. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997; 170: 422–5PubMedCrossRef
7.
Beasley CM, Dellva MA, Tamura RN, et al. Randomised doubleblind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment witholanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30PubMedCrossRef
8.
Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 53–60
9.
Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14(2): 87–96PubMedCrossRef
10.
Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 1996; 124(1–2): 57–73CrossRef
11.
Kumar V. Use of atypical agents in geriatric patients: a review. Int J Geriatr Psychopharmacology 1997; 1: 15–23
12.
13.
Madhusoodanan S, Brenner R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 1999; 12(2): 135–50CrossRef
14.
Wirshing WC, Marder SR, Van Putten T, et al. Acute treatment of schizophrenia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, 1994
15.
Crow TJ, MacMillan JF, Johnson AL, et al. Northwick Park study of first episodes of schizophrenia II. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120–7PubMedCrossRef
16.
Loebel AD, Lieberman JA, Alvir JMJ, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183–8PubMed
17.
Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993; 54 Suppl. 3: 13–7
18.
Marder SR. An approach to treatment resistance in schizophrenia. Br J Psychiatry 1999; Suppl. 37: 19–22
19.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994
20.
Meltzer H. Commentary: defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16(4): 563–5PubMedCrossRef
21.
Marder SR. Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 11: 26–30
22.
Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9): 789–96
23.
Wahlbeck K, Cheine M, Essali A, et al. Clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomised trials. Am J Psychiatry 1999; 156: 990–9PubMed
24.
Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effectsof clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151(12): 1744–52PubMed
25.
Essock SM, Hargreaves WA, Covell NH, et al. Clozapine’s effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32(4): 683–97PubMed
26.
Conley RR, Carpenter Jr WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154(9): 1243–7PubMed
27.
Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. J Psychopharmacol 1997; 11: 65–71PubMedCrossRef
28.
Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6): 825–35PubMed
29.
Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998; 155(4): 499–504
30.
Green MF, Marshall Jr BD, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154(6): 799–804PubMed
31.
Kern RS, Green MF, Marshall Jr BD, et al. Risperidone vs.haloperidol on reaction time, manual dexterity, and motorlearning in treatment-resistant schizophrenia patients. BiolPsychiatry 1998; 44(8): 726–32
32.
Kern RS, Green MF, Marshall BD, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull 1999; 25: 223–32PubMedCrossRef
33.
Kee KS, Kern RS, Marshall BD, et al. Risperidone versus haloperidolfor perception of emotion in treatment-resistant schizophrenia:preliminary findings. Schizophr Res 1998; 31: 159–65PubMedCrossRef
34.
Wirshing DA, Marshall Jr BD, Green MF, et al. Risperidone intreatment-refractory schizophrenia. Am J Psychiatry 1999;156(9): 1374–9PubMed
35.
Flynn SW, MacEwan GW, Altman S, et al. An open comparisonof clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry. 1998; 31(1): 25–9PubMedCrossRef
36.
Still DJ, Dorson PG, Crismon ML, et al. Effects of switchinginpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996; 47(12): 1382–4PubMed
37.
Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine comparedwith chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998; 155(7): 914–20PubMed
38.
Breier A, Hamilton SH. Comparative efficacy of olanzapineand haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999; 45(4): 403–11PubMedCrossRef
39.
Martin J, Gomez JC, Garcia BE, et al. Olanzapine in treatment-refractoryschizophrenia: results of an open-label study. J ClinPsychiatry 1997; 58(11): 479–83CrossRef
40.
Conley RR, Tamminga CA, Kelly DL, et al. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999; 46: 73–7PubMedCrossRef
41.
Dursun SM, Gardner DM, Bird DC, et al. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiatry 1999; 44: 701–4PubMed
42.
Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substanceabuse. Schizophr Res 1998; 33: 95–101PubMedCrossRef
43.
Sanders RD, Mossman D. An open trial of olanzapine in patients with treatment-refractory psychoses. J Clin Psychopharmacol 1999; 19: 62–6PubMedCrossRef
44.
Kumra A, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia:an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37: 377–85PubMedCrossRef
45.
Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine and haloperidol in schizophrenic patients with a history of, and a demonstrated, partial response to conventional antipsychotic treatment. Int J Psychopharmacol. In press
46.
Meltzer HY Risperidone and clozapine for treatment-resistantschizophrenia [letter]. Am J Psychiatry 1999; 156(7): 1126–7PubMed
47.
Rubin E. Risperidone and clozapine for treatment-resistant schizophrenia [letter]. Am J Psychiatry 1999; 156(7): 1127PubMed
48.
Dunayevich E, Chatterjee A. Risperidone and clozapine for treatment-resistantschizophrenia [letter]. Am J Psychiatry 1999;156(7): 1127PubMed
49.
Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia [letter]. Arch Gen Psychiatry 1989; 46(7): 672PubMedCrossRef
50.
May PS, Dencker J, Hubbard K, et al. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Wiesbaden: Vieweg, Branschweig, 1988: 22–3
51.
Stanilla JK, de Leon J, Simpson GM. Clozapine withdrawalresulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 1997; 58: 252–5PubMedCrossRef
52.
Klieser E, Lehman E, Kinzler E, et al. Randomised, double blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15 Suppl. 1: 45S–51SPubMedCrossRef
53.
Small JG, Miller MJ, Klapper MH. Risperidone versus clozapine in chronic schizophrenia [abstract no. NR724]. Poster presented at the annual meeting of the American Psychiatric Association: 1994 May; Philadelphia (PA)
54.
Daniel DG, Weinberger DR, Kleinman JE, et al. Risperidone versus clozapine in psychosis [abstract no. NR356]. Poster presented at the annual meeting of the American Psychiatric Association: 1994 May; Philadelphia (PA)
55.
Tollefson GD, Beasley-CM J, Tran PV, et al. Olanzapine versushaloperidol in the treatment of schizophrenia and schizoaffectiveand schizophreniform disorders: results of an internationalcollaborative trial. Am J Psychiatry 1997; 154(4): 457–65PubMed
56.
Pickar D, Owen RR, Litman RE, et al. Clinical and biologicresponse to clozapine in patients with schizophrenia. Crossovercomparison with fluphenazine. Arch Gen Psychiatry 1992;49(5): 345–53CrossRef
57.
Frazier JA, Gordon CT, McKenna K, et al. An open trial ofclozapine in 11 adolescents with childhood-onset schizophrenia.J Am Acad Child Adolesc Psychiatry 1994; 33: 658–63PubMedCrossRef
58.
Szigethy E, Brent S, Findling RL. Quetiapine for refractoryschizophrenia. J Am Acad Child Adolesc Psychiatry 1998; 37: 1127–8PubMedCrossRef
59.
Chincilla A, Vega M, Cebollada A, et al. A long term treatmentwith seroquel (quetiapine) in a severe schizophrenia patient.Eur Neuropsychopharmacol 1997; 7 Suppl. 2: S198–S199CrossRef
Metadata
Title
Role of Newer Atypical Antipsychotics in the Management of Treatment-Resistant Schizophrenia
Author
Prof. Robin A. Emsley
Publication date
01-06-2000
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 6/2000
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200013060-00003

Other articles of this Issue 6/2000

CNS Drugs 6/2000 Go to the issue

Leading Article

Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors

Adis Drug Evaluation

Metrifonate

Review Article

Atypical Antipsychotics in the Treatment of Bipolar Disorder

Disease Management

Epidemiology, Pathophysiology and Treatment of Pathological Gambling

Review Article

Agents in Development for Anxiety Disorders